Therapeutic Applications of Micro-RNA in Cancer Management
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 403
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is a disease characterized by the development of abnormal cells that divide uncontrollably and can infiltrate and destroy tissues. This disease is the second leading cause of death in the world, making it a major public health problem. Conventional cancer treatments such as chemotherapies, immunotherapy and targeted therapies are effective until the cancer becomes resistant to the treatment. Therefore, there must be a window of therapeutic options.
MiRNAs are small non-coding RNA sequences with a length of about 20 nucleotides that regulate gene expression. Their deregulation is associated with cancer, and they even act as oncogenes or tumor suppressor genes, playing an important role in tumor biology. In this sense, restoration of miRNA expression and inhibition of overexpressed miRNAs normalizes their function by reversing tumor cell phenotypes. Therefore, the idea of converting miRNAs into therapeutic agents is gaining relevance in this research field, through the use of synthetic molecules, nanoparticles, vesicles, quatsomes, etc., as vehicles for miRNAs to inhibit proliferation, cancer cell invasion, promote apoptosis, inhibit metastasis and increase sensitivity to treatments. This research is laying the groundwork for the application of miRNAs in cancer treatment.
The journal Pharmaceuticals invites both reviews and original articles that shed light on advances in the therapeutic uses of miRNAs for cancer treatment. The collection of manuscripts will be published as a Special Issue of the journal.
Dr. Alma D. Campos-Parra
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- miRNAs
- therapeutic applications
- miRNA treatments
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
